abrdn Healthcare Investors

HQH

Market cap $1.02B

abrdn Healthcare Investors offers a discounted entry into the healthcare sector, with a strong tilt toward biotechnology exposure and active management. HQH has recently outperformed both the S&P 500 and biotech benchmarks, driven by relatively smaller-cap or lesser-known holdings like QURE, ALNY, ARGX, and CYTK. HQH suits more aggressive investors comfortable with volatility over the long term, or can appeal to tactical exposure to a recovering biotech sector via a discounted CEF structure.

PHILADELPHIA , Nov. 11, 2025 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on November 28, 2025 to all shareholders of record as of November 21, 2025 (ex-dividend date November 21, 2025). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN) which will pay on January 12, 2026, to all shareholders of record as of November 21, 2025 (ex-dividend date November 21, 2025).

abrdn Healthcare Investors is downgraded to a sell due to persistent underperformance and heavy concentration in Biotechnology. HQH offers a high dividend yield of 11.3%, but its income focus comes at the expense of long-term capital appreciation and NAV growth. Peers like THQ and THW provide better diversification across healthcare sub-sectors and have delivered superior total returns over the past decade.

Paper wealth can disappear with a quote. We focus on real cash income from our holdings. We discuss our top picks from defensive sectors, offering yields of up to 11%.

PHILADELPHIA , Sept. 30, 2025 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF)  (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on September 30, 2025, on a per share basis to all shareholders of record as of September 23, 2025 (ex-dividend date September 23, 2025).

Berkshire Hathaway's purchase of UnitedHealth signals a potential bottom and renewed interest in the struggling healthcare sector. abrdn Healthcare Investors offers a 12.4% yield and trades at a -9.36% NAV discount, making it an attractive entry point. Key holdings in HQH have shown earnings recovery, and sector rotation may favor undervalued healthcare stocks as S&P 500 valuations remain high.

Healthcare spending continues to rise as Americans, on average, are getting older. We utilize funds to generate strong income from a growth-focused sector. Your retirement portfolio can readily pay your way!

PHILADELPHIA , Aug. 11, 2025 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on August 29, 2025 to all shareholders of record as of August 22, 2025 (ex-dividend date August 22, 2025). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN) which will pay on September 30, 2025, to all shareholders of record as of August 22, 2025 (ex-dividend date August 22, 2025).

HQH offers high yields with a biotech and small/mid-cap tilt, but relies on capital payouts, making it less tax-efficient and more volatile. Active management and venture capital-style investing add agility but increase risk, with portfolio holdings changing frequently and a heavy biotech concentration. Total returns have been uninspiring, with NAV erosion, funding payouts, and sector underperformance, especially compared to broader healthcare funds like BME.

Healthcare CEFs are under pressure from regulatory shifts, but sector defensiveness and discounted valuations can create long-term opportunities. Within the CEF structure, we also have the added benefit that comes with the discount/premium dynamic inherent in the structure. We are looking at two names today that present investors with attractive distributions and that are looking like decently discounted opportunities.